CD282 Antilichaam [TL2.1] (PE)

The TL2.1 monoclonal antibody specifically reacts with human CD282, the Toll-like receptor 2 (TLR2) . It is a type I transmembrane signaling receptor containing IL-1 receptor like intracellular domain and leucine-rich repeats (LRR) in the extracellular domain. CD282 is expressed on peripheral blood monocytes and is involved distinguishing bacterial lipoproteins. The TL2.1 antibody blocks the receptor and immunoprecipitates TLR2 from human mammary epithelial cells (HMEC) and peripheral blood mononuclear cells (PBMC) .

7097

O60603

Human

TL2.1

PE

Primary Antibodies

Innate Immunity

The monoclonal antibody was purified utilizing affinity chromatography and unreacted dye was removed from the product.

Batch dependent

Phosphate-buffered aqueous solution, ≤0.09% Sodium azide, may contain carrier protein/stabilizer, ph7.2.

None

Blue Ice

The product should be stored undiluted at 4˚ C and should be protected from prolonged exposure to light. Do not freeze.

Mouse IgG2a, kappa

The TL2.1 monoclonal antibody specifically reacts with human CD282, the Toll-like receptor 2 (TLR2) .

TLR2

Toll-like receptor 2

Homo sapiens

Vinnakota, K., Hu, F., Ku, M. C., Georgieva, P. B., Szulzewsky, F., Pohlmann, A., ... Kettenmann, H. (2013) . Toll-like receptor 2 mediates microglia/brain macrophage MT1-MMP expression and glioma expansion.Neuro-oncology,15 (11), 1457-1468.

Meng, G., Rutz, M., Schiemann, M., Metzger, J., Grabiec, A., Schwandner, R., ... Kirschning, C. J. (2004) . Antagonistic antibody prevents toll-like receptor 2driven lethal shock-like syndromes.Journal of Clinical Investigation,113 (10), 1473-1481.

TIL4, CD284, TLR2

Flow

Liquid